After struggling for three decades, SBT is finally emerging as a clinical reality. To become the standard therapy for the treatment of end-stage intestinal failure, SBT must offer a better quality of life, fewer risks, and lower costs than home TPN. To achieve this standard, protocols must be refined to obtain lower rates of rejection and infection as well as more consistent graft function.
